CEL-SCI Corporation (CVM)

CEL-SCI's stock price has been impacted by Q4 2024 earnings, share dilution, and public offerings. The company reported an EPS of -$0.09, exceeding expectations, but experienced significant stock volatility. Multiple public offerings in 2025, including one at a discount, led to a 37% drop in share price. Insider "purchases" were revealed to be restricted stock, potentially viewed negatively by investors.

CEL-SCI Corp. does not experience traditional demand seasonality. Its activities and financial performance are driven by clinical trial progress, regulatory milestones, and funding rounds rather than seasonal consumer demand.

CEL-SCI Corp. is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and infectious diseases. Its primary product, Multikine, is an immunotherapeutic agent that has completed Phase 3 clinical trials for advanced primary head and neck squamous cell carcinoma. The company is also developing the LEAPS technology for various conditions, including pandemic influenza and rheumatoid arthritis.

CEL-SCI Corp. is based in Vienna, Virginia, USA, focusing on its Phase 3 trial for head and neck cancer. It is pursuing regulatory developments in Saudi Arabia, including a Breakthrough Medicine Designation application for Multikine.

CEL-SCI's brand reputation is shaped by clinical development progress and financial activities. Positive Phase 3 trial results for Multikine and regulatory efforts in the U.S. and Saudi Arabia contribute positively. Financial challenges, including cash burn and dilutive stock offerings, have impacted investor confidence. The revelation about insider stock "purchases" could negatively affect transparency and investor trust.

CEL-SCI Corporation's ownership is concentrated among public and individual investors, contributing to stock price volatility. Major institutional owners include Vanguard Group Inc., Commonwealth Equity Services, Llc, and BlackRock, Inc. Insider ownership is relatively low but significant.